Oscine Therapeutics pipeline
Oscine’s platform targets multiple diseases with high unmet need and significant market potential
Oscine’s most advanced programs will enter the clinic in 2019/2020.
Globally, it is estimated that ~30% of MS patients have progressive disease.
210.000 SPMS patients in major markets
No drugs are approved for SPMS that help repair damaged nerves and induce remyelination
Prevalence of Pelizaeus-Merzbacher disease is estimated to be ~2 in 500,000 males; this X-linked condition rarely affects females. Patients often die of respiratory complications during infancy or early childhood
Despite the well understood disease course and pathophysiology, there are no treatment options